MedTrace Logo

Treatment of Chronic Lymphocytic Leukemia

NCT02757586 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2016-05-13

No results posted yet for this study

Summary

CLL is a disease of the elderly, identifying effective therapies with better toxicity profiles is thus a high priority, and targeted therapies may allow attainment of this goal.

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

GENETIC

shRNA

Using shRNA interfered the expression of the gene of CLL

Sponsors & Collaborators

  • Beijing Hospital

    collaborator OTHER_GOV

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Xiao-Jun Huang · professor

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-12-31
Completion
2019-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02757586 on ClinicalTrials.gov